Open AccessPioglitazone Stimulates Apolipoprotein A-I Production Without Affecting HDL Removal in HepG2 Cells
Author(s) -
Shucun Qin,
Tianjiao Liu,
Vaijinath S. Kamanna,
Moti L. Kashyap
Publication year - 2007
Publication title -
arteriosclerosis thrombosis and vascular biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.007
H-Index - 270
eISSN - 1524-4636
pISSN - 1079-5642
DOI - 10.1161/atvbaha.107.150193
Subject(s) - pioglitazone , apolipoprotein b , medicine , endocrinology , chemistry , cholesterol , type 2 diabetes , diabetes mellitus
Pioglitazone, an antihyperglycemic drug, increases plasma high-density lipoprotein (HDL)-cholesterol in patients with type 2 diabetes. The mechanisms by which pioglitazone regulate HDL levels are not clear. This study examined the effect of pioglitazone on hepatocyte apolipoprotein AI (apoA-I) and apoA-II production and HDL-protein/cholesterol ester uptake.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom